No profile data available.
Korro Bio, Inc. (KRRO) is a healthcare company in the multi-therapeutic drug manufacturing industry, based in Cambridge, United States, with about 57 full-time employees.
It reported revenue of $6.39 million for fiscal year 2025, up 181.5% from fiscal year 2024, and net income of -$117.26 million. Its market capitalization was $149.61 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia.
Korro Bio reported $6.39 million in revenue for fiscal year 2025, up 181.5% from $2.27 million in fiscal year 2024.
$149.61 million as of October 9, 2026.
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include ProQR Therapeutics N.v. (PRQR), Protara Therapeutics, Inc. (TARA), Tiziana Life Sciences Ltd (TLSA), Avidity Biosciences, Inc. (RNA).